Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Bringing MYC inhibition to the brain by ultrasound technology

Project description

New treatment for brain tumours and metastases

Primary and metastatic brain tumours are challenging to treat due to limited therapeutic options and the inability of most drugs to cross the restrictive blood-brain barrier (BBB). Inhibition of the MYC oncogene appears to be a promising strategy against these tumours, but the only clinically validated direct MYC inhibitor to date, OMO-103, cannot cross the BBB. The ERC-funded SonoMYC project will combine OMO-103 with the SonoCloud technology developed by France-based Carthera, which uses ultrasound to temporarily disrupt the BBB. The combination proposed could establish a novel treatment for primary and metastatic brain tumours by enabling OMO-103 delivery to the brain. This synergy could address the growing demand for brain tumour therapies.

Objective

Brain tumours and brain metastases pose a significant therapeutic challenge due to limited treatment options, fatally linked to high morbidity and mortality. Treatment of these cancers is hindered by the presence of the blood-brain barrier (BBB), that restricts the free passage of molecules larger than 400 daltons, reducing the effectiveness of therapeutically impermeable compounds. While deregulation of the MYC oncogene is a main feature of these cancers, to date, effective and clinically-viable, BBB-permeable MYC inhibitors are lacking.
This project proposes to combine Omomyc (OMO-103), developed in our laboratory and the best characterized, direct MYC inhibitor, with Carthera's SonoCloud technology, which temporarily disrupts the BBB using ultrasound. Omomyc is currently under clinical evaluation for other systemic aggressive cancers, under the sponsorship of Peptomyc, a spin-off from our lab, focusing on clinical application of our inhibitors. This new investigation will establish the feasibility and viability of its commercial development into a disruptive novel treatment for primary and metastatic brain tumours. This combination aims to enhance OMO-103 delivery to the brain, to improve its therapeutic efficacy and reducing any potential systemic side effects. The synergy between these technologies has the potential to generate new intellectual properties, facilitate technology transfers, and address a growing market for brain tumour therapies. By overcoming the BBB challenge and directly targeting MYC, this approach could significantly impact brain cancer treatment and create new commercial opportunities.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2025-POC

See all projects funded under this call

Host institution

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON (VHIO)
Net EU contribution
€ 150 000,00
Address
CALLE NAZARET 115-117
08035 Barcelona
Spain
Region
Este Cataluña Barcelona
Activity type
Research Organisations
Links
Total cost
No data

Beneficiaries (1)